Objective The potential mechanism of“Bupleurum-Salvia miltiorrhiza” in the treatment of chronic hepatitis B was analyzed by means of network pharmacology and molecular docking. Methods The effective components and targets of“Bupleurum-Salvia miltiorrhiza” were obtained by using references and databases like TCMSP, Drugbank, Uniprot and so on. Genecards, Drugbank and OMim were used to search for targets related to chronic hepatitis B, and Venny database, String database and Cytoscape platform to build effective components - target interaction network. The function and pathway enrichment analysis of the core targets were carried out by R language to predict the potential key components and action targets of“Bupleurum-Salvia miltiorrhiza” in the treatment of chronic hepatitis B. Autodock and Pymol software were further used to conduct molecular docking between its active components and HBcAg, HBeAg and HBsAg in order to analyze the mechanism and feasibility of its treatment. Results We obtained 73 active components of“Bupleurum - Salvia miltiorrhiza” in the treatment of chronic hepatitis B. There were 985 potential targets of chronic hepatitis B. According to the network of common compounds and targets of“Bupleurum-Salvia miltiorrhiza” in the treatment of chronic hepatitis B, there were 67 effective active ingredients such as quercetin, luteolin, kaempferol and tanshinone, and 88 common targets such as PTGS2, ADRB2, HSP90A1 and ESR1. Through GO and KEGG analysis, it can be seen that it is involved in biological processes such as cytokine receptor binding, as well as signaling pathways such as hepatitis B, to play an important role in treatment. The docking of core components with target proteins showed that quercetin and luteolin had a good affinity with HBcAg, HBeAg and HBsAg. Conclusion Through network pharmacology and molecular docking, the complex action characteristics of“Bupleurum-Salvia miltiorrhiza” in the treatment of chronic hepatitis B were fully reflected, which provides theoretical basis and new therapeutic direction for further experiment and clinical practice.